Brief: Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation By U.S. FDA For Patients With Pretreated Extensive-Stage Small Cell Lung Cancer
18/08/2025 14:45
Daiichi Sankyo Co Ltd 4568.T: IFINATAMAB DERUXTECAN GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA FOR PATIENTS WITH PRETREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER Source text: ID:nBwgLbJLa Further company coverage: 4568.T